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Although historically thymoma and thymic carcinoma have been treated surgically, radiation
therapy also has an important role, either as postoperative therapy to reduce the risk of
mediastinal recurrence or as part of definitive treatment for patients who cannot undergo
surgery. Induction chemotherapy and molecular targeted agents may also be appropriate
for thymic carcinoma, the behavior of which resembles non-small-cell lung carcinoma more
than that of thymoma or invasive thymoma and is increasingly being treated like lung can-
cer. We present here a review of current therapies for thymic malignancies and briefly
discuss the potential benefits from novel technologies for such treatment.
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Thymic malignancies, although the most common primary neo-
plasms of the anterior mediastinum, are relatively rare. The course
of disease can range from indolent to quite aggressive, making the
choice of treatment and analysis of outcomes challenging. The
few prospective trials that have included patients with advanced-
stage disease involved heterogeneous treatments (1). Retrospective
and prospective analyses have demonstrated promising survival
rates for patients undergoing trimodality therapy (chemotherapy,
surgery, and radiation therapy) for advanced invasive thymoma
(2–5) or thymic carcinoma (6–8). However, investigations that
include large numbers of patients from several institutions are
sparse, particularly those that compare patients who received
different types of treatments.
INDICATIONS FOR ADJUVANT (POSTOPERATIVE) RADIATION
THERAPY
R0 (COMPLETELY RESECTED) THYMIC MALIGNANCIES
In general, radiation should be considered more strongly as the
risk of recurrence increases. Therefore, for patients with the lowest
likelihood of recurrence (i.e., completely resected Masaoka stage
I thymoma), radiation can be safely omitted (9–11). For those
at intermediate risk of local recurrence after complete resection,
i.e., those with aggressive tumor histologies (such as thymic car-
cinoma) or Masaoka stage II and stage III disease, retrospective
evidence exists both to support (9, 12) and contradict (13–15)
claims of benefit from adjuvant radiotherapy after complete resec-
tion. In general, our institutional practice includes postoperative
radiation for completely resected Masaoka-Koga stage III thy-
moma and stage II or III thymic carcinoma. Risk assessment and
stratification is usually done in a multidisciplinary setting and dri-
ves the choice of adjuvant treatment. The International Thymic
Malignancy Interest Group (ITMIG) published a set of definitions
and reporting guidelines for the use of radiation therapy for thymic
malignancies in 2011 (16). Pertinent recommendations for post-
operative therapy are as follows. First, the term “postoperative”
should be used for situations in which the tumor is resected and
no residual disease is evident on imaging. If gross disease is present
on postoperative imaging, then the disease should be defined as
“recurrent” and the intent as “radiation for postoperative disease.”
Second, the minimum acceptable dose for postoperative R0 dis-
ease is 50 Gy in 5 weeks. Finally, radiation to elective nodal regions
is not recommended, and the extent of malignancy before surgery
should be used as a guide for designing the treatment fields.
MICROSCOPIC POSITIVE MARGINS (R1) AND GROSS DISEASE (R2)
Radiation for R1 or R2 thymic malignancies should be started
within 3 months of surgical resection. Doses between 40 and
64 Gy are most appropriate for microscopically positive margins,
whereas doses of 54 Gy or higher should be used for gross dis-
ease; both should be given in standard fractions of 1.8–2.0 Gy
(16). Patients with positive margins should be considered for con-
current chemotherapy and radiotherapy, especially patients with
thymic carcinoma.
INDICATIONS FOR INDUCTION (PREOPERATIVE) RADIATION
THERAPY
Some patients with thymoma and thymic carcinoma present
with disease that is unresectable at diagnosis. Neoadjuvant
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chemotherapy can increase the likelihood of resectable disease for
patients who are otherwise eligible for surgery. Potential induc-
tion regimens include chemotherapy alone (17, 18), radiation
alone (19, 20), and combined chemotherapy and radiation (3).
Chemotherapeutic regimens are generally cisplatin-based; reg-
imens used in prior studies have included cyclophosphamide,
doxorubicin, cisplatin, and prednisone or cisplatin and etoposide
(18, 21). In some cases, patients undergo preoperative radiation
therapy and then, after surgical resection, are considered for adju-
vant treatment. Radiation therapy in this context can be difficult
to deliver without exceeding dose constraints, and the cumula-
tive radiation dose should be considered carefully. As is true for
postoperative therapy, preoperative therapy should not include
elective nodal regions but rather should encompass the gross area
of involvement with an appropriate margin.
INDICATIONS FOR DEFINITIVE RADIATION THERAPY
Definitive radiation therapy is generally used for patients who are
not candidates for surgery because of either the extent of disease
at diagnosis or other medical conditions. Because chemotherapy
is a known radiation sensitizer, the combination of chemother-
apy and radiation is considered most likely to control disease in
these circumstances (5, 22–24). A multimodality approach such
as trimodality therapy or definitive concurrent chemoradiation in
unresectable cases is recommended for thymic carcinoma regard-
less of disease stage (25). Notably, only one-third of patients with
thymic carcinoma are able to undergo a complete resection after
such therapy (26). Definitive radiation therapy for unresectable
disease is considered analogous to radiation therapy for disease
that recurs after surgical resection; for such cases, we recommend
radiation doses of 60–66 Gy to encompass gross disease plus a mar-
gin for microscopic regions at risk. The corresponding radiation
dose when radiation is to be given with chemotherapy as definitive
therapy is 54 Gy.
INDUCTION CHEMOTHERAPY AND MOLECULAR TARGETED THERAPIES
Induction chemotherapy regimens for the treatment of thymic
carcinoma and invasive thymoma have typically involved three
cycles of cyclophosphamide, doxorubicin, cisplatin, and pred-
nisone, to be followed by surgery. However, the advent of targeted
therapies over the past decade has led to a variety of approaches
being tested for their ability to improve disease control. Molec-
ular characterization of thymomas and thymic carcinoma have
shown that cKIT (CD117) is overexpressed in thymic carcinomas
but not in thymomas (27, 28), and vascular endothelial growth
factor (VEGF)-A and the VEGF receptor (VEGFR) are often over-
expressed in thymic carcinomas (29). In contrast, mutations in the
epithelial growth factor receptor are quite uncommon in thymic
malignancies and seem to be limited to a small proportion of
Asian patients (30, 31). These and other findings have led to sev-
eral trials to test the safety and efficacy of targeted agents for thymic
malignancies, including cKIT inhibitors, anti-EGFR therapies, and
histone deacetylase inhibitors. To date, the results of these tri-
als have been disappointing (30, 32). However, as more data on
the molecular characteristics of thymic carcinoma are collected
through multi-institutional tumor registries and databases, clini-
cal trials of individualized care based on the molecular makeup of
each individual tumor could lead to substantial breakthroughs in
the treatment of this disease.
RADIATION TECHNIQUES
Because of the central location of thymic malignancies and
the relatively high doses used in radiation therapy, we strongly
recommend the use of conformal techniques, such as three-
dimensional conformal radiation therapy (3D-CRT), intensity-
modulated radiation therapy (IMRT), or, if available, proton beam
therapy because of the physical properties of the proton particles,
which lead to lower doses being deposited both proximal and distal
to the target volume. In addition, because tumors can show sub-
stantial changes in shape or size over the course of several weeks
of radiation therapy, we recommend that when radiation is to be
used as definitive therapy, adaptive replanning should be consid-
ered (33). Adaptive replanning involves obtaining additional CT
scans at approximately halfway through treatment and evaluat-
ing tumor coverage to determine if the treatment plans should
be modified. Several studies have shown that adaptive replanning
can significantly minimize the radiation dose to normal tissues
(34, 35).
For locally advanced disease, standard radiation treatment
fields would include the tumor plus a margin if the radiation is to
be given before surgery or as definitive therapy, and the tumor bed
plus a margin if the radiation is to be given after surgery. Because
lymph node metastases are rare, elective nodal coverage is not rou-
tinely recommended. Previous studies have examined the role of
hemithoracic radiation therapy to prevent pleural dissemination.
However, the doses that could be achieved while simultaneously
meeting normal tissue constraints (10–20 Gy) were lower than
are typically used for microscopic disease (36–38). Although this
method has been reported to be safe and perhaps to lead to modest
reductions in pleural recurrences, these findings are provocative
at best, and these doses may well be ineffective for adequately
controlling disease. The advent of conformal techniques, particu-
larly IMRT, may enable the delivery of higher doses of radiation,
which would increase the probability of disease control, while
still limiting the dose to the surrounding esophagus, spinal cord,
heart, and contralateral lung. Indeed, IMRT has been used to treat
mesothelioma with promising results (39, 40).
LONG-TERM CONSEQUENCES OF RADIATION ON THE HEART
AND VASCULATURE
Abundant evidence suggests that long-term survivors of mediasti-
nal radiation therapy are at risk of both acute and chronic cardiac
sequelae. With regard to acute effects, the dose and fractionation of
the radiation and the volume of heart irradiated all affect the risk
of pericarditis and pericardial effusion (41). Given the close phys-
iologic association between perfusion and ventilation, one might
expect that radiation to the heart could affect lung function and
vice versa. In one clinical study, investigators found that several
heart dose-volume variables predicted radiation pneumonitis and
that the fit of a model predicting pneumonitis was improved by
the incorporation of cardiac variables (42). The risk of cardiac and
other side effects is also affected by the exact location of the irra-
diated field. Short-term surrogates of long-term toxicity such as
findings on cardiovascular imaging or biomarker correlates would
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be helpful for identifying which patients at greatest risk for car-
diac events. In the meantime, we recommend the continued use
of advanced radiation therapy technologies such as IMRT, proton
beam therapy, use of 4D CT-based imaging and treatment plan-
ning, and adaptive planning when possible to minimize the dose
to mediastinal structures for patients with thymic disease, many
of whom will survive for several decades and thus will live to see
the long-term consequences of irradiation of these vital organs.
EFFECTS OF RADIATION THERAPY ON SURVIVAL AND
DISEASE CONTROL
Studies evaluating whether the inclusion of radiation therapy
affects disease control and survival in thymic carcinoma are sparse
because of the rarity of the disease; indeed, to the best of our
knowledge no prospective trials have been done that compare
outcomes between patients who have or have not received radia-
tion therapy. Most published retrospective reports have focused on
invasive thymoma, with some studies indicating that radiation is
beneficial for locally advanced disease after surgery (8, 43–45) and
others not demonstrating a clear advantage (46–48). Thymic car-
cinoma is often analyzed together with locally advanced invasive
thymoma in an attempt to increase patient numbers and statis-
tical power. In perhaps the best analysis of this type, a study of
1,320 patients from Japan with thymic malignancies, the authors
compared adjuvant regimens in patients with completely resected
stage III-IV thymoma and thymic carcinoma (14). They found no
significant differences in survival between patients who received
adjuvant radiation and those who received no further treatment.
A subanalysis of only patients with thymic carcinoma also showed
no difference in survival between those who received radiation
versus no further treatment; however, that subanalysis did show
that patients who received adjuvant chemoradiation for thymic
carcinoma had worse outcomes than patients who received either
radiation alone or observation. Notably, however, the size of these
subgroups was small, with 24 receiving chemoradiation, 33 receiv-
ing radiation, and 16 receiving observation. A multivariate analysis
of factors predicting survival among 290 patients with thymic car-
cinoma in the Surveillance, Epidemiology, and End Results data-
base revealed that the extent of surgical excision, Masaoka stage,
and race were associated with survival but receipt of radiation was
not (49). In a much smaller study of 26 patients, investigators from
Taiwan found that surgery and postoperative radiation achieved
5-year local control rates of 77%, but nearly 50% of patients expe-
rienced distant metastases (6). Finally, in a study of 14 patients
with thymic carcinoma treated at the Gunma Prefectural Cancer
Center in Japan, patients who received radiation had better out-
comes than those who did not, and those investigators concluded
that radiation has an important role in the treatment of thymic
carcinoma (50). Clearly large prospective studies are needed to
definitively answer this question.
As is true of studies of survival, analyses of patterns of fail-
ure after treatment for thymic carcinoma have generally been
small and retrospective. In general, thymic carcinoma tends to
recur distantly rather than locally, and pleural and extrathoracic
metastases tend to drive overall survival (51, 52). For this rea-
son, the development of effective targeted agents will be impor-
tant in improving treatment outcomes in this disease. However,
significant local invasion such as that into the great vessels or heart
portends worse locoregional control and progression-free survival
(53, 54). Further, both early-stage disease and achievement of com-
plete resection have been shown to be associated with improved
prognosis (55, 56), highlighting the role of radiation therapy in
maximizing the likelihood of local control and optimizing survival
outcomes.
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